ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 5, 2017
WBA, ESRX, CVS: Earnings Update for the Pharmacy Services Industry
Image Source: Mike Mozart. The first-quarter earnings performance across the pharmacy services industry has been a proverbial mixed bag with uncertainty continuing to weigh on performance. We continue to be interested in the industry for its defensive and strong free cash flow characteristics that bode well for dividend hikes and share repurchases going forward. We like CVS the most.
May 3, 2017
SEC Approves Financial Weapon of Mass Destruction and More Earnings Reports
Let’s talk about quadruple-leveraged ETFs, Apple’s and Altria’s earnings reports, Coach’s fundamental improvement, Gilead’s fall from grace, IBM’s ongoing deterioration and more.
May 2, 2017
How the FDA’s Delay of Baricitinib Impacts Eli Lilly and Incyte
Image Source: Paul Sableman. The FDA dealt Eli Lilly and Incyte an unforeseen blow recently by rejecting their marketing application for Rheumatoid Arthritis candidate Baricitinib. Where does the duo go from here?
May 1, 2017
Seeking Balance: What’s Happening in the Crude Oil and Iron Ore Markets
Image Source: Sollven Melindo. Commodity prices are notoriously volatile as the global markets often struggle to maintain a sustainable balance of supply-demand. Let’s take a look at some recent developments and coming events that are impacting the prices of crude oil and iron ore.
May 1, 2017
Big Pharma, Big Dividends: Earnings Update Featuring Eli Lilly, Bristol-Myers Squibb, and AbbVie
Image Source: Drugs.com. Let’s dive into some recent developments and earnings reports from three big pharma players with meaningful income considerations.
Apr 28, 2017
More First-Quarter Earnings Flying In: GM, Ford, Big Oil and More
Image Source: General Motors. GM’s dividend yield and valuation opportunity are incredible, while Microsoft’s free cash flow generation and solid net cash position speak to tremendous dividend strength. We liked what we saw out of Union Pacific during the first quarter, and you have to be aware of Big Oil’s bloated balance sheets. All of this and more included in this piece.
Apr 28, 2017
Alphabet, Intel, MLPs and More
Let’s keep the good times going, would you say?
Apr 26, 2017
S&P 500 Poised to Make New Highs…Again?
The equity markets have welcomed a strong earnings season thus far, but valuation risk and tail uncertainties remain, not the least of which is the possibility of failed tax reform in the US.
Apr 20, 2017
Reflecting on Recent Report Updates: Favorites in an Overheated Market and Other Themes
It’s been some time since we’ve updated members on our recent fair value estimate updates. Let’s take a look at the opportunities that exist in some of our favorite portfolio holdings, as well as some key themes driving recent fair value estimate changes across our coverage universe.
Apr 18, 2017
United’s Passenger Debacle An Immaterial Investment Consideration
Image Source: Tomás Del Coro. The major airlines in the US have done a fantastic job capitalizing on the ongoing upswing in air travel demand, but their economically-sensitive business models remain the most operationally-leveraged out of any industry group in our coverage. This should be investors' biggest concern: A downturn in the global economy and competitive pricing pressures are far greater worries for investors than United’s recent passenger debacle. However, as with many news-oriented items (as opposed to materially-relevant, investment-related items), United's misstep is making headlines in a big way. Though the footage in this article is appalling, investors in airline stocks have much more important things to worry about, in our view.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.